The 2020 PharmaTimes International Clinical Researcher of the Year will be closing for entry at midnight this Thursday the 23rd of January.
News
Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
Government health commitments just a ‘pipedream’
The plans were “ambitions”, and primary care is not being given the time, support and funding it needs.
Vitrakvi deemed ‘not cost-effective’ by NICE
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
Sepsis death rates ‘double’ previous figures
The new study included data from low- and middle-income countries, bringing the estimated total from 5.3 million deaths to 11 million.
Janssen submits Spravato expansion in EU
The J&J division seeks to expand the use to adults with major depressive disorder who have current suicidal ideation with intent.
A&E to scrap waiting targets?
The suggestion comes after December showed the “worst waiting times on record.”
NICE ‘OK’ for Lynparza
In a trial the drug stalled cancer growth for around 13.6 months compared to placebo.
Scientists discover ‘skin cancer suppressor’
Although it’s early stages, the research could eventually help develop new ways to combat melanoma.
UK cell and gene clinical trials up 45% from 2018
The industry currently supports over 3,000 jobs, with 1,700 roles in manufacturing and bioprocessing.
NICE rejects Keytruda, asks for more info
The decision, which is for HNSCC, brings the UK “further out of step with clinical practice in the rest of the world.”
Could gut bacteria guard against Parkinson’s?
The results are the latest in a number of recent studies which have found a link between brain function and the digestive system.
Cyber attacks hit more than half of healthcare orgs in last year
Despite the vulnerability to cyber attacks, just 24% of companies have an adequate level of budget allocated to cyber security.
PTC submits MAA for new gene therapy
The company expects a CHMP decision in the second half of 2020.
Horizon enlists Mammoth in CRISPR move
The San Fransisco-based biotech built the first CRISPR-based detection platform for diagnostics.
